IS6379A - Fjölhringa alkýlpúrin sem mótlyf adenósíns - Google Patents
Fjölhringa alkýlpúrin sem mótlyf adenósínsInfo
- Publication number
- IS6379A IS6379A IS6379A IS6379A IS6379A IS 6379 A IS6379 A IS 6379A IS 6379 A IS6379 A IS 6379A IS 6379 A IS6379 A IS 6379A IS 6379 A IS6379 A IS 6379A
- Authority
- IS
- Iceland
- Prior art keywords
- adenosine
- alkylpyrins
- polycyclic
- disorders
- adenosine antagonists
- Prior art date
Links
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 108010060263 Adenosine A1 Receptor Proteins 0.000 abstract 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16519199P | 1999-11-12 | 1999-11-12 | |
PCT/US2000/031058 WO2001034610A1 (en) | 1999-11-12 | 2000-11-13 | Polycycloalkylpurines as adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6379A true IS6379A (is) | 2002-05-10 |
Family
ID=22597852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6379A IS6379A (is) | 1999-11-12 | 2002-05-10 | Fjölhringa alkýlpúrin sem mótlyf adenósíns |
Country Status (35)
Country | Link |
---|---|
US (5) | US6649600B1 (is) |
EP (3) | EP2070930A1 (is) |
JP (1) | JP2003513982A (is) |
KR (2) | KR20080027971A (is) |
CN (2) | CN101255162A (is) |
AT (1) | ATE424403T1 (is) |
AU (1) | AU784556B2 (is) |
BG (1) | BG65720B1 (is) |
BR (1) | BR0015545A (is) |
CA (1) | CA2390496A1 (is) |
CY (1) | CY1110512T1 (is) |
CZ (1) | CZ20021614A3 (is) |
DE (1) | DE60041710D1 (is) |
DK (1) | DK1230243T3 (is) |
EA (1) | EA005211B1 (is) |
EE (1) | EE05365B1 (is) |
ES (1) | ES2323357T3 (is) |
GE (1) | GEP20043303B (is) |
HK (1) | HK1049155B (is) |
IL (1) | IL149487A0 (is) |
IS (1) | IS6379A (is) |
ME (1) | MEP42208A (is) |
MX (1) | MXPA02004796A (is) |
NO (1) | NO328956B1 (is) |
NZ (2) | NZ527917A (is) |
PL (1) | PL206890B1 (is) |
PT (1) | PT1230243E (is) |
RS (1) | RS50381B (is) |
SI (1) | SI1230243T1 (is) |
SK (1) | SK287311B6 (is) |
TR (1) | TR200201260T2 (is) |
TW (1) | TWI272270B (is) |
UA (1) | UA77391C2 (is) |
WO (1) | WO2001034610A1 (is) |
ZA (1) | ZA200203701B (is) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02004795A (es) * | 1999-11-12 | 2005-07-01 | Biogen Inc | Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos. |
DE60041710D1 (de) * | 1999-11-12 | 2009-04-16 | Biogen Idec Inc | Polycycloalkylpurine als adenosinrezeptorantagonisten |
UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
DE10145193C1 (de) | 2001-09-13 | 2003-03-13 | Sachtler Gmbh & Co Kg | Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten |
CA2489179A1 (en) * | 2002-06-12 | 2003-12-24 | Biogen Idec Ma Inc. | Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
US7495004B2 (en) | 2002-06-17 | 2009-02-24 | Glaxo Group Limited | Purine derivatives as liver X receptor agonists |
WO2004009594A2 (en) * | 2002-07-19 | 2004-01-29 | Aryx Therapeutics | Xanthine derivatives having adenosine a1-receptor antagonist properties |
US7202252B2 (en) | 2003-02-19 | 2007-04-10 | Endacea, Inc. | A1 adenosine receptor antagonists |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
WO2004096228A1 (en) * | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
WO2005009343A2 (en) | 2003-06-06 | 2005-02-03 | Endacea, Inc. | A1 adenosine receptor antogonists |
EP2314574A1 (en) * | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors |
WO2007059330A2 (en) * | 2005-11-17 | 2007-05-24 | Medkura Inc. | Cubane nucleoside analogs |
JP2009532479A (ja) * | 2006-04-06 | 2009-09-10 | ノヴァカーディア,インク. | アデノシンa1受容体アンタゴニストと抗痙攣薬の同時投与 |
CN101085785B (zh) * | 2006-06-06 | 2011-09-21 | 中国科学院上海药物研究所 | 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途,以及包括该化合物的组合物 |
WO2007149366A1 (en) * | 2006-06-16 | 2007-12-27 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
MX2009000548A (es) * | 2006-07-17 | 2009-05-28 | Tyratech Inc | Composiciones y metodos para controlar insectos. |
WO2008121893A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
US20080242684A1 (en) * | 2007-03-29 | 2008-10-02 | Howard Dittrich | Methods of administration of adenosine a1 receptor antagonists |
EP2222676A4 (en) * | 2007-12-21 | 2011-10-26 | Endacea Inc | A1-adenosine receptor antagonistic |
US20100063071A1 (en) * | 2008-06-13 | 2010-03-11 | Kiesman William F | Therapeutic compositions and related methods of use |
WO2010011917A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
WO2011063268A2 (en) | 2009-11-19 | 2011-05-26 | Biogen Idec Ma Inc | Novel synthetic methods |
JP5892613B2 (ja) * | 2009-12-04 | 2016-03-23 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | ポリマー材料 |
CN101709034B (zh) * | 2009-12-14 | 2017-05-31 | 大连九信精细化工有限公司 | 双环[2.2.2]辛烷‑1,4‑二羧酸单甲酯的合成方法 |
TWI538905B (zh) * | 2010-12-22 | 2016-06-21 | H 朗德貝克公司 | 雙環[3.2.1]辛基醯胺衍生物及其用途 |
WO2013003383A1 (en) | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
KR20150130398A (ko) * | 2013-03-14 | 2015-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클로 [2.2.2] 산 gpr120 조절제 |
LT6401B (lt) | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
US10633315B2 (en) | 2016-10-19 | 2020-04-28 | Eastman Chemical Company | Synthesis of bicyclo[2.2.2]octanes |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
CA3075892C (en) | 2017-09-14 | 2024-01-23 | Daiichi Sankyo Company, Limited | Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases |
EP3694831A1 (en) | 2017-10-11 | 2020-08-19 | Eastman Chemical Company | Synthesis of bicyclo[2.2.2]octane derivatives |
SG11202003827YA (en) | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
US10836899B2 (en) | 2018-12-13 | 2020-11-17 | Eastman Chemical Company | Polyesters with specified crystallization half-times |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0011399A1 (en) * | 1978-11-11 | 1980-05-28 | FISONS plc | N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them |
DE3843117A1 (de) | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
US5270316A (en) | 1989-10-20 | 1993-12-14 | Kyowa Hakko Kogyo Co., Ltd. | Condensed purine derivatives |
DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
JPH0559056A (ja) * | 1991-02-25 | 1993-03-09 | Kyowa Hakko Kogyo Co Ltd | キサンチン誘導体 |
JPH04270222A (ja) | 1991-02-25 | 1992-09-25 | Kyowa Hakko Kogyo Co Ltd | 脳機能改善剤 |
CA2061544A1 (en) * | 1991-02-25 | 1992-08-26 | Fumio Suzuki | Xanthine compounds |
JPH04346986A (ja) | 1991-05-23 | 1992-12-02 | Kyowa Hakko Kogyo Co Ltd | トリチウム標識化されたキサンチン誘導体 |
DE69229257D1 (de) * | 1991-11-08 | 1999-07-01 | Kyowa Hakko Kogyo Kk | Xanthinderivate zur Behandlung der Demenz |
JP3115128B2 (ja) * | 1991-11-08 | 2000-12-04 | 協和醗酵工業株式会社 | キサンチン誘導体 |
US5336769A (en) | 1992-02-17 | 1994-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
US5342841A (en) * | 1992-03-12 | 1994-08-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
JPH0616668A (ja) * | 1992-03-12 | 1994-01-25 | Kyowa Hakko Kogyo Co Ltd | キサンチン誘導体 |
TW252044B (is) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
US5384176A (en) * | 1992-12-11 | 1995-01-24 | Zimmerman; Richard C. | Phenolic acid sulfate esters for prevention of marine biofouling |
WO1994016702A1 (en) | 1993-01-26 | 1994-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for irregular bowel movement |
JP3729874B2 (ja) * | 1993-04-07 | 2005-12-21 | 協和醗酵工業株式会社 | キサンチン誘導体 |
US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
AU7675598A (en) | 1997-06-16 | 1999-01-04 | Kyowa Hakko Kogyo Co. Ltd. | Hepatic edema remedy |
AU7675498A (en) | 1997-06-16 | 1999-01-04 | Kyowa Hakko Kogyo Co. Ltd. | Preventive and remedy for drug-induced nephropathy |
DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE69912375T2 (de) | 1998-04-24 | 2004-08-19 | Cv Therapeutics, Palo Alto | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
ES2284256T3 (es) | 1998-07-02 | 2007-11-01 | Kyowa Hakko Kogyo Co., Ltd. | Medicamentos para la diabetes. |
DE60041710D1 (de) * | 1999-11-12 | 2009-04-16 | Biogen Idec Inc | Polycycloalkylpurine als adenosinrezeptorantagonisten |
MXPA02004795A (es) * | 1999-11-12 | 2005-07-01 | Biogen Inc | Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos. |
EP1338595B1 (en) * | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
WO2004009594A2 (en) * | 2002-07-19 | 2004-01-29 | Aryx Therapeutics | Xanthine derivatives having adenosine a1-receptor antagonist properties |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
AU2005212816C1 (en) * | 2004-02-14 | 2010-03-04 | Glaxosmithkline Llc | Novel compounds |
-
2000
- 2000-11-13 DE DE60041710T patent/DE60041710D1/de not_active Expired - Lifetime
- 2000-11-13 SI SI200031029T patent/SI1230243T1/sl unknown
- 2000-11-13 BR BR0015545-4A patent/BR0015545A/pt not_active Application Discontinuation
- 2000-11-13 SK SK663-2002A patent/SK287311B6/sk not_active IP Right Cessation
- 2000-11-13 CZ CZ20021614A patent/CZ20021614A3/cs unknown
- 2000-11-13 EP EP09151275A patent/EP2070930A1/en not_active Withdrawn
- 2000-11-13 EE EEP200200247A patent/EE05365B1/xx not_active IP Right Cessation
- 2000-11-13 AT AT00978546T patent/ATE424403T1/de active
- 2000-11-13 EA EA200200560A patent/EA005211B1/ru not_active IP Right Cessation
- 2000-11-13 KR KR1020087005528A patent/KR20080027971A/ko not_active Application Discontinuation
- 2000-11-13 AU AU16000/01A patent/AU784556B2/en not_active Ceased
- 2000-11-13 PT PT00978546T patent/PT1230243E/pt unknown
- 2000-11-13 CN CNA2008100921415A patent/CN101255162A/zh active Pending
- 2000-11-13 KR KR1020027006093A patent/KR100863761B1/ko not_active IP Right Cessation
- 2000-11-13 US US09/711,543 patent/US6649600B1/en not_active Expired - Fee Related
- 2000-11-13 WO PCT/US2000/031058 patent/WO2001034610A1/en active IP Right Grant
- 2000-11-13 CN CNB008164398A patent/CN100390178C/zh not_active Expired - Fee Related
- 2000-11-13 CA CA002390496A patent/CA2390496A1/en not_active Abandoned
- 2000-11-13 DK DK00978546T patent/DK1230243T3/da active
- 2000-11-13 IL IL14948700A patent/IL149487A0/xx not_active IP Right Cessation
- 2000-11-13 EP EP10183076A patent/EP2305684A1/en not_active Withdrawn
- 2000-11-13 NZ NZ527917A patent/NZ527917A/en not_active IP Right Cessation
- 2000-11-13 ME MEP-422/08A patent/MEP42208A/xx unknown
- 2000-11-13 PL PL356033A patent/PL206890B1/pl not_active IP Right Cessation
- 2000-11-13 ES ES00978546T patent/ES2323357T3/es not_active Expired - Lifetime
- 2000-11-13 GE GE4819A patent/GEP20043303B/en unknown
- 2000-11-13 RS YUP-338/02A patent/RS50381B/sr unknown
- 2000-11-13 MX MXPA02004796A patent/MXPA02004796A/es active IP Right Grant
- 2000-11-13 JP JP2001537323A patent/JP2003513982A/ja active Pending
- 2000-11-13 NZ NZ519426A patent/NZ519426A/en not_active IP Right Cessation
- 2000-11-13 EP EP00978546A patent/EP1230243B1/en not_active Expired - Lifetime
- 2000-11-13 TR TR2002/01260T patent/TR200201260T2/xx unknown
- 2000-11-13 UA UA2002064822A patent/UA77391C2/uk unknown
- 2000-12-15 TW TW089123845A patent/TWI272270B/zh active
-
2002
- 2002-05-09 ZA ZA200203701A patent/ZA200203701B/xx unknown
- 2002-05-10 IS IS6379A patent/IS6379A/is unknown
- 2002-05-10 NO NO20022238A patent/NO328956B1/no not_active IP Right Cessation
- 2002-05-31 BG BG106762A patent/BG65720B1/bg unknown
- 2002-12-23 HK HK02109310.2A patent/HK1049155B/zh not_active IP Right Cessation
-
2003
- 2003-08-21 US US10/646,454 patent/US20040067966A1/en not_active Abandoned
-
2006
- 2006-07-10 US US11/484,805 patent/US7579354B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/487,764 patent/US20070015732A1/en not_active Abandoned
-
2009
- 2009-02-10 US US12/368,469 patent/US20090221821A1/en not_active Abandoned
- 2009-05-21 CY CY20091100543T patent/CY1110512T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6379A (is) | Fjölhringa alkýlpúrin sem mótlyf adenósíns | |
CY1106560T1 (el) | Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων | |
WO2004072033A3 (en) | Pyrazoles and methods of making and using the same | |
WO2004021989A3 (en) | Imidazolopyridines and methods of making and using the same | |
HK1085724A1 (en) | 3,6-disubstituted azabicyclo 3.1.0-hexane derivatives as muscarinic receptor antagonists | |
DE60230683D1 (de) | 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat | |
GB9815618D0 (en) | Treatment of dyskinesia | |
CA2275686A1 (en) | Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors | |
NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
ATE256126T1 (de) | 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen |